Tonix Pharmaceuticals to Present at World Vaccine Congress Washington 2025
Tonix Pharmaceuticals (NASDAQ: TNXP) to showcase TNX-102 SL for fibromyalgia management at World Vaccine Congress Washington 2025. Company also receives $34 million contract for antiviral development. Exciting advancements in biopharmaceuticals.
This news highlights Tonix Pharmaceuticals' advancements in biopharmaceuticals, signaling potential breakthroughs in pain management and infectious disease treatment. Investors and individuals interested in innovative healthcare solutions should take note of Tonix's developments.